Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab with nab-paclitaxel and lobaplatin as neoadjuvant therapy for stage II–III TNBC
ChiCTR2500114072Phase 4Not yet recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Dec 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iparomlimab, tuvonralimab, paclitaxel and lobaplatin in triple-negative breast cancer (TNBC), sponsored by Southwest Hospital of Army Medical University. Primary endpoint: Total pathological complete response (tpCR). Planned start Dec 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimabpaclitaxellobaplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2500114072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114072.